Theravance/Astellas Antibiotic Telavancin “Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Complete response to agency will not require additional trials, but may include revising label, re-analysis of data, Theravance CEO says.
You may also be interested in...
FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date
Firm says FDA and company audits of telavancin clinical trial data are progressing well; no predictions on how long process may take.
FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date
Firm says FDA and company audits of telavancin clinical trial data are progressing well; no predictions on how long process may take.
FDA Wants More Ceftobiprole Data From J&J/Basilea
Racing against Theravance's "approvable" telavancin, company will supply added results in diabetic foot infections.